Literature DB >> 8531220

GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.

J S Schneider1, A Kean, L DiStefano.   

Abstract

GM1 ganglioside has been shown to stimulate recovery of the damaged dopamine system under a number of different circumstances. In addition to rescue of damaged dopamine neurons, the present study assessed the ability of GM1 to enhance the synthesis of dopamine in remaining nigrostriatal neurons following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure. There was a significantly greater accumulation of L-dopa 30 min after aromatic amino acid decarboxylase inhibition with NSD-1015 (100 mg/kg) and an increase in the ratio of L-dopa to dopamine in MPTP+GM1-treated mice than in mice that received only MPTP. This effect of GM1 on dopamine synthesis was dependent upon the degree of initial damage to the nigrostriatal dopamine system. That is, the GM1 effect on dopamine synthesis could not be demonstrated in mice with greater than 95% striatal dopamine loss and 75% substantia nigra dopamine neuron loss. These results suggest that in addition to previously reported effects of GM1 on rescue and repair of dopaminergic neurons, GM1 may also have the ability to enhance dopamine synthesis in residual dopaminergic neurons. Direct effects on dopamine neurochemistry may contribute to functional improvement seen after GM1 treatment in various models of parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8531220     DOI: 10.1002/jnr.490420113

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  11 in total

1.  Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.

Authors:  Italo Mocchetti; Alessia Bachis; Rachel L Nosheny; Gianluigi Tanda
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

2.  GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Authors:  Jay S Schneider; Franca Cambi; Stephen M Gollomp; Hiroto Kuwabara; James R Brašić; Benjamin Leiby; Stephanie Sendek; Dean F Wong
Journal:  J Neurol Sci       Date:  2015-06-16       Impact factor: 3.181

3.  A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Authors:  Jay S Schneider; Stephen M Gollomp; Stephanie Sendek; Amy Colcher; Franca Cambi; Wei Du
Journal:  J Neurol Sci       Date:  2012-11-28       Impact factor: 3.181

Review 4.  A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease.

Authors:  J S Schneider
Journal:  Glycoconj J       Date:  2021-05-26       Impact factor: 2.916

5.  Mice lacking major brain gangliosides develop parkinsonism.

Authors:  Gusheng Wu; Zi-Hua Lu; Neil Kulkarni; Ruchi Amin; Robert W Ledeen
Journal:  Neurochem Res       Date:  2011-03-12       Impact factor: 3.996

6.  Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.

Authors:  Jay S Schneider; Thomas N Seyfried; Hyo-S Choi; Sarah K Kidd
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

Review 7.  Ganglioside biochemistry.

Authors:  Thomas Kolter
Journal:  ISRN Biochem       Date:  2012-12-19

Review 8.  Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.

Authors:  Nouara Yahi; Coralie Di Scala; Henri Chahinian; Jacques Fantini
Journal:  Glycoconj J       Date:  2021-07-30       Impact factor: 2.916

Review 9.  Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson's Disease.

Authors:  Paula A Q Videira; Margarida Castro-Caldas
Journal:  Front Neurosci       Date:  2018-06-07       Impact factor: 4.677

10.  Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease.

Authors:  Jay S Schneider
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.